Athena Sharifi-Razavi

Dr. Athena Sharifi-Razavi


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2020 in New Microbes and New Infections
Verified
Journal Article
Open access
ASAthena Sharifi-Razavi
Athena Sharifi-Razavi
NKN. Karimi
N. Karimi
NRN. Rouhani
N. Rouhani
Pneumonia appears to be the most common manifestation of coronavirus disease 2019 (COVID-19), but some extrapulmonary involvement, such as gastrointestinal, cardiac and renal, has been reported. The limited clinical data about the virus's behavior to date, especially extrapulmonary symptoms, suggest that we should be aware of the possibility of initial cerebrovascular manifestations of COVID-19.

15 December 2020 in Neurology
Verified
Journal Article
Closed access
PDF file
SFSebastian Fridman
Sebastian Fridman
MBMaria Bres Bullrich
Maria Bres Bullrich
AJAmado Jimenez-Ruiz
Amado Jimenez-Ruiz
PCPablo Costantini
Pablo Costantini
PSPalak Shah
Palak Shah
LSLuciano A. Sposato
Luciano A. Sposato
Objectives: To investigate the hypothesis that strokes occurring in patients with COVID-19 have distinctive features, we investigated stroke risk, clinical phenotypes, and outcomes in this population. Methods: We performed a systematic search resulting in 10 studies reporting stroke frequency among COVID-19 patients, which were pooled with one unpublished series from Canada. We applied random-effects meta-analyses to estimate the proportion of stroke among COVID-19. We performed an additional systematic search for cases series of stroke in COVID-19 patients (n=125) and we pooled these data with 35 unpublished cases from Canada, USA, and Iran. We analyzed clinical characteristics and in-hospital mortality stratified into age groups (70 years). We applied cluster analyses to identify specific clinical phenotypes and their relationship with death. Results: The proportion of COVID-19 patients with stroke (1.8%, 95%CI 0.9-3.7%) and in-hospital mortality (34.4%, 95%CI 27.2-42.4%) were exceedingly high. Mortality was 67% lower in patients 70 years-old (OR 0.33, 95%CI 0.12-0.94, P=0.039). Large vessel occlusion was twice as frequent (46.9%) as previously reported and was high across all age groups, even in the absence of risk factors or comorbidities. A clinical phenotype characterized by older age, a higher burden of comorbidities, and severe COVID-19 respiratory symptoms, was associated with the highest in-hospital mortality (58.6%) and a 3x higher risk of death than the rest of the cohort (OR 3.52, 95%CI 1.53-8.09, P=0.003). Conclusions: Stroke is relatively frequent among COVID-19 patients and has devastating consequences across all ages. The interplay of older age, comorbidities, and severity of COVID-19 respiratory symptoms is associated with an extremely elevated mortality.

1 September 2020 in New Microbes and New Infections
Verified
Journal Article
Open access
MMM. Mardani
M. Mardani
SNS. Alireza Nadji
S. Alireza Nadji
KSK. Aghazadeh Sarhangipor
K. Aghazadeh Sarhangipor
ASAthena Sharifi-Razavi
Athena Sharifi-Razavi
MBM. Baziboroun
M. Baziboroun
Coronavirus disease 2019 (COVID-19) infection can involve many organs, such as central nervous system, including in relapse. We describe the case of a 64-year-old woman with microbiologically confirmed COVID-19–induced respiratory distress whose treatment resulted in a negative nasopharyngeal swab reverse transcriptase PCR (RT-PCR) result for COVID-19. However, after a few weeks, relapse occurred, as indicated by symptoms of acute meningoencephalitis. Results of COVID-19 RT-PCR testing from her cerebrospinal fluid, nasopharyngeal and tracheal aspiration specimens became positive again, but COVID-19 serum antibodies were negative. We therefore note that symptoms with neurologic involvement can be one of COVID-19's first presentations, or they can appear at relapse. Regular evaluation of patients during convalescence is therefore necessary.

20 September 2021 in Journal of Stroke and Cerebrovascular Diseases
Verified
Journal Article
Closed access
PSPayam Sasanejad
Payam Sasanejad
LHLeila Afshar Hezarkhani
Leila Afshar Hezarkhani
SAShahram Arsang-Jang
Shahram Arsang-Jang
GTGeorgios Tsivgoulis
Georgios Tsivgoulis
AGAbdoreza Ghoreishi
Abdoreza Ghoreishi
MAMahmoud Reza Azarpazhooh
Mahmoud Reza Azarpazhooh

19 July 2022 in Clinical Case Reports
Verified
Journal Article
Open access
MBMohammad Barary
Mohammad Barary
ASAthena Sharifi-Razavi
Athena Sharifi-Razavi
NRNasser Rakhshani
Nasser Rakhshani
TSTerence T. Sio
Terence T. Sio
Soheil EbrahimpourSoheil Ebrahimpour
Soheil Ebrahimpour
MBMama Baziboroun
Mama Baziboroun
The common side effects of COVID‐19 vaccination were mostly self‐restricted local reactions that quickly resolved. Nevertheless, rare autoimmune hepatitis cases have been reported in some vaccinated with mRNA COVID‐19 vaccines. This article presents a young man who developed fulminant hepatitis a few days after vaccination with the first dose of the AstraZeneca COVID‐19 vaccine. A 35‐year‐old man was admitted to our hospital with generalized weakness, abdominal pain, and jaundice. He received the first dose of the AstraZeneca COVID‐19 vaccine 8 days earlier. He was admitted to the hospital with a chief complaint of abdominal pain. On admission and because of his high D‐dimers, low platelet count, and low Fibrinogen level, vaccine‐induced immune thrombosis thrombocytopenia was suspected, which was ruled out later. Then, after a surge in his liver function tests, decreasing platelet, and abnormal clotting tests, fulminant hepatitis was considered for this patient. Several bacterial, viral, and autoimmune etiologies were then suspected, with all ruled out. Thus, fulminant hepatitis secondary to his AstraZeneca COVID‐19 vaccine was confirmed. Unfortunately, he died 3 days later of disseminated intravascular coagulopathy, after which a liver necropsy was performed, indicating drug/toxin‐induced hepatitis.

29 September 2025 in BMC Neurology
Verified
Journal Article
Open access
PDF file
FRFatemeh Rahimi
Fatemeh Rahimi
AZAshraf Zarvani
Ashraf Zarvani
FFFarzad Fayedeh
Farzad Fayedeh
ASAthena Sharifi-Razavi
Athena Sharifi-Razavi
The optimal dosing of alteplase for acute ischemic stroke remains debated, particularly regarding the balance between efficacy and bleeding risks. This study compared outcomes between standard-dose (0.9 mg/kg) and low-dose (< 0.85 mg/kg) alteplase in an Iranian cohort. In this retrospective cohort study, 328 patients with acute ischemic stroke treated at Boo-Ali Sina Hospital (2016–2023) were analyzed. Participants were divided into standard-dose (n = 177) and low-dose (n = 151) groups. Primary outcomes included functional independence (modified Rankin Scale [mRS] 0–2 at 3 months) and symptomatic intracranial hemorrhage (sICH). Secondary outcomes comprised mortality and hemorrhagic complications. Multivariable logistic regression adjusted for age, NIHSS score, and comorbidities. The low-dose group had significantly lower rates of sICH (5.29% vs. 13.55%, p = 0.01), fatal bleeding (1.98% vs. 7.90%, p = 0.03), and in-hospital mortality (8.6% vs. 15.81%, p = 0.01). Parenchymal hemorrhage-1 occurred exclusively with standard dosing (15.9% vs. 0%). Three-month functional outcomes were comparable (mRS 0–2: 53.6% vs. 46.9%, p = 0.22). Adjusted analyses confirmed reduced odds of any ICH (OR 0.34, 95% CI 0.18–0.64) and fatal ICH (OR 0.23, 95% CI 0.06–0.83) with low-dose therapy. Low-dose alteplase was associated with fewer hemorrhagic complications and lower mortality while maintaining comparable functional outcomes to standard dosing. These findings support its potential as a safer alternative, particularly in resource-limited settings where cost and drug availability pose challenges. Randomized trials are needed to validate these results.